U.S. markets closed

Amarin Takes Proactive Steps to Support Public Health Priorities

DUBLIN, Ireland and BRIDGEWATER, N.J., March 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a leader in preventative cardiovascular risk reduction therapy, today announced actions in support of public health initiatives to combat the COVID-19 pandemic.

The COVID-19 pandemic is a significant threat to public health throughout the world. WHO1, many countries2, and the majority of states3 in the United States have recently declared emergencies and implemented strategies designed to contain spread of the virus through social distancing and other methods. Social distancing at the early stages of a pandemic is critical to stem the trajectory of disease proliferation. In support of social distancing, public officials have taken numerous actions: international travel has been restricted, schools have been shut down, public events have been cancelled and group gatherings have been minimized. These steps are being taken to minimize personal interaction as much as possible to stem disease spread and “flatten the curve”. In the field of pharmaceutical marketing, increased social contact, such as interactions between sales representatives with healthcare providers, has the potential to counter-act these important public health initiatives and to put our employees and people in doctors’ offices at unnecessary risk. 

Accordingly, as Amarin is intently focused on improving public health by reducing cardiovascular risk, currently the most damaging disease in the industrialized world, and consistent with our corporate values, we have announced immediate suspension of field based face-to-face interactions for the next two weeks, until Monday, March 30th. To directly support patient care, Amarin plans to continue to provide digital and internet-based educational materials and copay cards and will continue to ship samples. It is too early for the company to assess the impact of the COVID-19 pandemic and these actions on Amarin’s revenue growth and previously reported revenue guidance. Such actions follow reports in early March of record prescription levels, and record new prescription levels, for VASCEPA® (icosapent ethyl).  We understand that other pharmaceutical companies are taking similar actions. We will continue during this period with non-personal promotion initiatives and use some of the time for further training of our field personnel. We will continue to monitor the situation and provide updates at an appropriate time.

“As a company focused for more than a decade on fighting cardiovascular disease, which in the United States alone results in one stroke, heart attack or death every 14 seconds, we are determined to do our part to protect public health and the health of our many valued employees,” said John Thero, president and chief executive officer of Amarin. “We have developed a roadmap of remote working activities for us to continue to help many patients with persistent cardiovascular risk, including using virtual customer tools to maintain contact and enhanced sales training. Our efforts are designed to do our part to help reduce the spread of COVID-19, protect the health of our employees and their families and preserve healthcare resources at a critical interim period for those most in need and, ultimately, to save lives. We applaud the dedication and efforts of healthcare professionals internationally as they prioritize their own efforts to address the public health crisis presented by COVID-19. And, we express our condolences to everyone who is suffering from this pandemic. We will work to continue our diligent efforts to bring to healthcare professionals and the public our contribution to improved treatment of cardiovascular risk, which is not only an enormous and growing medical issue worldwide but also a leading factor of increased risk to those infected by COVID-19.”

In addition, the company responded to questions regarding whether its supply chain for Vascepa is likely to be significantly impacted by COVID-19. Amarin’s supply chain is diversified and therefore mitigates geographical risks. None of Amarin’s manufacturing is conducted in China. Furthermore, Amarin has built significant stockpiles of VASCEPA in the United States. VASCEPA is reported to be available in pharmacies throughout the United States and similarly available in other countries where it is approved for sale.  From the information that is currently available, Amarin does not believe coronavirus will have a major impact, if any impact, on its ability to supply VASCEPA to support its growing business.

About Amarin
Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit www.amarincorp.com.

About Cardiovascular Disease
Cardiovascular disease is an enormous and growing medical issue worldwide.4, 5 In the United States alone, a heart attack, stroke, death or other major cardiovascular event is experienced every 14 seconds.6

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk of experiencing a cardiovascular event. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent cardiovascular risk, especially those patients with high triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35% – but that still leaves 65-75% of risk remaining.7 People with high triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.8,9,10

About VASCEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times and is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.

Indications and Limitation of Use
VASCEPA is indicated:

  • As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and

    º established cardiovascular disease or

    º diabetes mellitus and two or more additional risk factors for cardiovascular disease.
  • As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.

  • VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.

  • It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. 
  • VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
  • Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
  • Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
  • Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

  • Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents for bleeding should be monitored.

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA, as set forth below:

Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in
Patients with Elevated Triglyceride Levels and Other Risk Factors for
Cardiovascular Disease in REDUCE-IT

vs Placebo
N = 4089
n (%)
Incidence Rate
(per 100 patient years)
N = 4090
n (%)
Incidence Rate
(per 100 patient years)
Hazard Ratio (95% CI)
Primary composite endpoint
Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE) 705
4.3 901
5.7 0.75
(0.68, 0.83)
Key secondary composite endpoint
Cardiovascular death, myocardial infarction, stroke (3-point MACE) 459
2.7 606
3.7 0.74
(0.65, 0.83)
Other secondary endpoints
Fatal or non-fatal myocardial infarction 250
1.5 355
2.1 0.69
(0.58, 0.81)
Emergent or urgent coronary revascularization 216
1.3 321
1.9 0.65
(0.55, 0.78)
Cardiovascular death [1] 174
1.0 213
1.2 0.80
(0.66, 0.98)
Hospitalization for unstable angina [2] 108
0.6 157
0.9 0.68
(0.53, 0.87)
Fatal or non-fatal stroke 98
0.6 134
0.8 0.72
(0.55, 0.93)
[1] Includes adjudicated cardiovascular deaths and deaths of undetermined causality.
[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.


Forward-Looking Statements
This press release contains forward-looking statements, including Amarin efforts to stem the COVID-19 virus and cardiovascular disease, efforts to continue to help patients with persistent cardiovascular risk, such as through virtual customer tools to maintain contact and enhanced sales training and Amarin’s current believe about the impact of COVID-19 on its ability to supply VASCEPA to support its growing business. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. As circumstances change, the proactive steps taken by Amarin may be extended and it current outlook may change. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with the commercial success of pharmaceutical products such as VASCEPA, reliance on third parties in the VASCEPA supply chain and uncertainties related to virus containment efforts worldwide. In addition, Amarin's ability to effectively commercialize VASCEPA will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for VASCEPA through education, marketing and sales activities, to achieve market acceptance of VASCEPA, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to maintain exclusivity through patent protection and to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information
Investor and Media Inquiries:
Elisabeth Schwartz
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315

Lee M. Stern
Solebury Trout
In U.S.: +1 (646) 378-2992



1 https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2 https://www.theguardian.com/world/2020/mar/15/100m-europeans-on-lockdown-as-countries-battle-coronavirus
3 https://www.businessinsider.com/california-washington-state-of-emergency-coronavirus-what-it-means-2020-3
4 American Heart Association. Heart Disease and Stroke Statistics – 2019 Update: A Report from the American Heart Association. Published January 31, 2019.
5 American Heart Association / American Stroke Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.
6 American Heart Association: Heart Disease and Stroke Statistics -- 2019 At-a-Glance.
7 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
8 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.
9 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.
10 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.

  • Bank of America’s Race to Avoid Public Shaming Underscores the Perils of the Crisis

    Bank of America’s Race to Avoid Public Shaming Underscores the Perils of the Crisis

    The drama began when California Governor Gavin Newsom called out the bank for not offering 90-day grace periods to mortgage borrowers affected by the coronavirus, despite such pledges by rivals including JPMorgan Chase & Co. and Wells Fargo & Co. A journalist tweeted the lashing, and then Corden reposted it to his 10.7 million followers. The bank raced to correct what it called the governor's mistake. Just over an hour later, the firm promised Corden it would defer payments on home loans for as long as the crisis requires.

  • Business

    The Dow Ignored the Spread of Coronavirus Last Week. It Won’t Be Able to Anymore.

    As the disease has spread, fears about the possible death toll and the extent of the economic disaster roiled global financial markets. The Dow Jones Industrial Average rallied more than 20% off its low, putting it in a bull market, at least by some definitions, though it remains down 24.2% on the year. It is far from contained, and Covid-19, the respiratory disease caused by the virus, continues to spread.

  • Is Abbott A Buy After Gaining FDA Blessing For Its Coronavirus Test?
    Investor's Business Daily

    Is Abbott A Buy After Gaining FDA Blessing For Its Coronavirus Test?

    So, while the medical company's sales and earnings have grown consistently for several years, Abbott isn't lining up with CAN SLIM rules for investing. Investors are advised to seek companies with recent quarterly earnings and sales growth of 20%-25%. The bigger, the better.

  • The Airlines Most in Danger of Going Under During the Crisis

    The Airlines Most in Danger of Going Under During the Crisis

    Airlines could lose a quarter of a trillion dollars in revenue this year, according to the International Air Transport Association, as travel comes to a standstill with countries locked down to fight the coronavirus. Most carriers will go bankrupt by the end of May if they can't find support, Sydney-based CAPA Centre for Aviation said last week. Using the Z-score method developed by Edward Altman in the 1960s to predict bankruptcies, Bloomberg News filtered out listed commercial airlines to identify the ones most at risk of going bust, based on available data.

  • Zoom Technology shares suspended
    Yahoo Finance Video

    Zoom Technology shares suspended

    Zoom Technologies shares were suspended through April 8th, after the stock was confused with Zoom Video. Yahoo Finance's Julie Hyman breaks down the news.

  • Warren Buffett Is Only Making Money On Three Coronavirus Stocks
    Investor's Business Daily

    Warren Buffett Is Only Making Money On Three Coronavirus Stocks

    The coronavirus stock market crash is costing investors trillions. Buffett's Berkshire Hathaway is down nearly $60 billion on its U.S.-listed holdings this year. Online retailer Amazon.com, drugmaker Biogen and consumer staples retailer Kroger, are the only stocks in Berkshire Hathaway's lineup of 51 U.S.-listed stocks that are up this year.

  • Business
    Financial Times

    Investors should brace for another market dive

    At the height of the market turmoil during the previous financial crisis, a Federal Reserve Bank of New York official confidently told me they would keep throwing stuff at the wall until something stuck. This week the US central bank ran some moves from its 2008 playbook — and then went far beyond it. Adding to the open-ended buying of US government bonds, the Fed will load up on investment-grade corporate debt for the first time.

  • What's Next for the Markets? Here's What the Charts and Data Say

    What's Next for the Markets? Here's What the Charts and Data Say

    While psychology data continues to send a positive message, the McClellan one-day oscillators have been pushed well into overbought territory, suggesting some pause/retracement (already being exhibited Friday) of the recent rally. On the Charts All the major equity indices closed higher Thursday with positive internals on the NYSE and Nasdaq as trading volumes declined from the prior session. Further technical improvement was seen on the charts as all the indices, with the exceptions of the Dow Jones Transports (see below) and Value Line Arithmetic Index, which closed above their near-term resistance levels, while the Nasdaq Composite, Nasdaq 100, and Value Line closed above their near-term ...

  • Six High Dividend Stocks You Can Count On
    Investor's Business Daily

    Six High Dividend Stocks You Can Count On

    It's easy to chase high dividend stocks — and even easier to lose money on them if they fall. There's a better way to find high dividend yields you can count on to make you money — which includes stocks like REIT Coresite Realty, banks like N B T Bancorp and retailer Home Depot. What's an investor looking for high dividend stocks to do then?

  • Gold Forecast – The Real Bottom Should Come in May
    FX Empire

    Gold Forecast – The Real Bottom Should Come in May

    I'm very bullish on gold long-term and believe prices are going much, much higher. But in the meantime, I think we need to be careful. Our cycle work indicates the next sustainable low may not arrive until May or June.

  • Dead deals, slashed prices: Coronavirus drags down Southern California home sales
    LA Times

    Dead deals, slashed prices: Coronavirus drags down Southern California home sales

    For context, research from Zillow shows that during the 2003 SARS outbreak that lasted for several months in Hong Kong, the city's housing market essentially froze in place. Home prices didn't fall much, while the number of transactions plunged as people kept their distance from one another to save lives. After the epidemic was over, transactions snapped back to normal volumes,” Zillow chief economist Svenja Gudell wrote in a recent report, noting the bounce back corresponded with a similar rebound in gross domestic product.

  • Trump faces off with General Motors over ventilators
    Yahoo Finance Video

    Trump faces off with General Motors over ventilators

    Yahoo Finance's Sibile Marcellus discusses General Motors' move to produce ventilators with Ventec, after President Trumo tweeted in part "As usual with “this” General Motors, things just never seem to work out."

  • Will you get a ‘coronavirus check’? $2 trillion stimulus package explained
    Yahoo Finance

    Will you get a ‘coronavirus check’? $2 trillion stimulus package explained

    Congress has passed a $2.2 trillion coronavirus stimulus package to help Americans affected by the coronavirus pandemic. The bill includes direct cash assistance, additional unemployment funds, and tax credits to employers. The most well-known piece of the bill — stimulus checks — is available only to eligible Americans, based on tax returns.

  • Denver-based national restaurant company cuts staff by 97% to preserve cash
    American City Business Journals

    Denver-based national restaurant company cuts staff by 97% to preserve cash

    Denver's The One Group Hospitality (NYSE: STKS) — parent company to the STK steakhouse and Kona Grill chains — has cut its workforce from roughly 4,000 employees to less than 100 in order to hold onto cash during the coronavirus crisis, its CEO said Thursday. Most of its 20 STK locations worldwide and 24 Kona Grill stores are operating with skeleton crews of two to three employees who are cooking and offering the normally full-service restaurant menus for takeout and delivery only because of coronavirus restrictions, CEO Emanuel “Manny” Hilario said during the company's quarterly earnings call. Four domestic and two international STK restaurants have had to close up shop altogether temporarily, he added.

  • Business
    Fox Business

    Which oil stocks are best positioned when crude rebounds from crash?

    The battered S&P 500 Energy Sector has raced into bull-market territory despite crude oil prices treading near 18-year lows. The sector gained 22.27 percent in the five days through Wednesday, making it the third-fastest trek from a bear market low to a bull market in history, buoying holders of the sector-linked Energy Select SPDR Fund. “The pain trade is clearly a rally in highly-indebted companies, and many oils clearly fit that category,” wrote Paul Sankey, managing director at Mizuho Securities.

  • Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'

    Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'

    Answering questions from callers, former hedge fund manager and CNBC “Mad Money” host Jim Cramer revealed his favorite stock picks Thursday. Smartphone maker BlackBerry Ltd (NYSE: BB)  is clearly not Cramer's favorite. Describing it as “absolutely nothing,” he suggested a caller take their money if there's anything left and buy Marvell Technology Group Ltd (NASDAQ: MRVL) because “5G is king.”

  • Hotels are 'hurting big-time' and many will 'go under,' travel industry expert says
    Yahoo Finance

    Hotels are 'hurting big-time' and many will 'go under,' travel industry expert says

    Congress signed off on a $2 trillion coronavirus stimulus bill on Friday that provides aid to individuals, small businesses, and large corporations — including America's airlines, which will get billions in direct grants in exchange for giving the federal government stakes. The plight of airlines commands much focus, as their businesses have all but come to a stand-still amid the coronavirus pandemic. CBS Travel Editor Peter Greenberg forecasts a grim future for hotel chains, telling Yahoo Finance's On The Move on Thursday that many will “go under.”

  • Here's 'the problem' with the IRS coronavirus tax filing extension, one expert says
    Yahoo Finance

    Here's 'the problem' with the IRS coronavirus tax filing extension, one expert says

    As the coronavirus escalates across the United States, businesses and individuals are concerned with how this will affect their taxes, despite the deadline being extended to July 15. That changed deadline is not a blanket extension for all taxes, tax litigation consultant and author of “Small Business Tax Guide” Daniel Pilla told Yahoo Finance's On the Move on Thursday. It only applies to income taxes and not employment taxes businesses have to pay, he pointed out.

  • 3 “Strong Buy” Dividend Stocks Yielding At Least 10%

    3 “Strong Buy” Dividend Stocks Yielding At Least 10%

    The company showed revenue gains in the fourth quarter, which was a relief after it missed in Q3. The Q4 top line came in at $2.1 billion, beating the forecast by 2%, and growing a half-percent sequentially. EPS missed the forecast by one cent, coming in at 24 cents per share.

  • These Are The 5 Best Stocks To Buy And Watch Now
    Investor's Business Daily

    These Are The 5 Best Stocks To Buy And Watch Now

    The most recent stock market uptrend has turned into a fierce bear market. The Dow Jones Industrial Average, S&P 500 index and Nasdaq composite have been slammed due to reverberations from the coronavirus becoming a global pandemic. The virus is already hitting economic growth and global supply chains.

  • Business
    American City Business Journals

    Cruise company stocks sink further as aid is left out of stimulus package

    Stock price gains for public cruise companies began to quickly disappear as it became apparent the government's stimulus package won't be the saving grace investors in South Florida's cruise giants were hoping for. The bill, passed by both the U.S. Senate and House of Representatives, states that in order for a business to qualify for capital, companies must be organized in the U.S., and have the majority of its operations and employees based in the country. That disqualifies Doral-based Carnival Corp.

  • Mortgage rates fall sharply as the Federal Reserve brings stability to the mortgage market

    Mortgage rates fall sharply as the Federal Reserve brings stability to the mortgage market

    Mortgage rates seesawed lower this week after the Federal Reserve stepped in to provide some assurance to lenders who were at a loss as to how to price home loans amid the disruptions caused by the coronavirus emergency. The 30-year fixed-rate mortgage dropped to 3.50% during the week ending March 26, Freddie (FMCC) reported Thursday. That represented a significant decrease of 15 basis points from last week, when rates surged to the highest level since January.

  • Dow Keeps Bulk Of 4,382-Point Gain Since March Low; What 5 Charts Say About The Market Now
    Investor's Business Daily

    Dow Keeps Bulk Of 4,382-Point Gain Since March Low; What 5 Charts Say About The Market Now

    In one of its most dramatic rebounds in decades, the Dow Jones Industrial Average finished the week up almost 13% despite suffering a 4% loss Friday. Data from the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University showed confirmed coronavirus cases surpassing the 100,000 level in the U.S. Yet from a March 23 low of 18,213, the 30-stock blue-chip index has ripped as much as 24% higher. At least eight of the 30 Dow Jones industrials stocks fell 7 points or more.

  • America’s Shortage Of This Metal Keeps Trump Up At Night

    America’s Shortage Of This Metal Keeps Trump Up At Night

    So, when a Canadian junior miner emerges as the owner of three properties in Ontario that could provide the only new supply of one of these critical metals, North America sees hope. The metal is cesium, and the miner is Power Metals--a little-known company with a big-name geologist that just put itself on the critical metals map. The 5G revolution, American military defense, healthcare and even time itself are dependent on this one critical metal that China monopolizes and that the U.S. is desperate to get more of.

  • Aurora Cannabis (ACB) Stock Gets a Recession Boost; What’s Next?

    Aurora Cannabis (ACB) Stock Gets a Recession Boost; What’s Next?

    The global economic shutdown due to the coronavirus was a potential nightmare for Aurora Cannabis (ACB). The Canadian cannabis company is in the middle of cutting capacity and costs for the new reality in the market while trying to avoid running out of cash. A complete shutdown of cannabis stores would've crushed any remaining hope in financial improvements at the business, but the market has seen the opposite effect of the shutdown actually lead to a boost to cannabis sales as consumers stay at home.